{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bone+Marrow+Neoplasms&page=2",
    "query": {
      "condition": "Bone Marrow Neoplasms",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bone+Marrow+Neoplasms&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T06:22:24.870Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00723099",
      "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Aggressive Non-Hodgkin Lymphoma",
        "Chronic Myelogenous Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Indolent Non-Hodgkin Lymphoma",
        "Lymphoma",
        "Mixed Phenotype Acute Leukemia",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Follicular Lymphoma",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent T-Cell Non-Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Chronic Myelogenous Leukemia",
        "Refractory Follicular Lymphoma",
        "Refractory Hodgkin Lymphoma",
        "Refractory Lymphoplasmacytic Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Small Lymphocytic Lymphoma",
        "T-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 73,
      "start_date": "2008-06-25",
      "completion_date": "2018-07-31",
      "has_results": true,
      "last_update_posted_date": "2019-12-27",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Salt Lake City, Utah + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00723099"
    },
    {
      "nct_id": "NCT00022906",
      "title": "Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Iodine-131 Anti-B1 Antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corixa Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "1999-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022906"
    },
    {
      "nct_id": "NCT04517851",
      "title": "Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis Transformation in Essential Thrombocythemia",
        "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
        "Primary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Elotuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-02-10",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04517851"
    },
    {
      "nct_id": "NCT02793544",
      "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome (MDS)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Chemotherapy-sensitive Lymphoma",
        "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma",
        "Acute Myelogenous Leukemia (AML)",
        "Acute Biphenotypic Leukemia (ABL)",
        "Acute Undifferentiated Leukemia (AUL)"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI) 200cGy on Day -1",
          "type": "RADIATION"
        },
        {
          "name": "Infusion of non-T-cell depleted bone marrow on Day 0",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1",
          "type": "RADIATION"
        },
        {
          "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -6 and -5",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -2 and -1",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -5 and -4",
          "type": "DRUG"
        },
        {
          "name": "Post-HCT Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "15 Years to 70 Years"
      },
      "enrollment_count": 80,
      "start_date": "2016-12",
      "completion_date": "2020-03",
      "has_results": true,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 11,
      "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02793544"
    },
    {
      "nct_id": "NCT02546284",
      "title": "Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myelomonocytic Leukemia (CMML)"
      ],
      "interventions": [
        {
          "name": "lenzilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Humanigen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-07",
      "completion_date": "2020-02",
      "has_results": false,
      "last_update_posted_date": "2020-02-28",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02546284"
    },
    {
      "nct_id": "NCT02477878",
      "title": "Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Lymphoma",
        "Multiple Myeloma",
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "BPX-501",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bellicum Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-07",
      "completion_date": "2033-01",
      "has_results": false,
      "last_update_posted_date": "2022-07-12",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477878"
    },
    {
      "nct_id": "NCT01291784",
      "title": "Anti-TGF-beta Therapy in Patients With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelofibrosis",
        "Primary Myelofibrosis",
        "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
        "Post-essential Thrombocythemia Related Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "monoclonal antibody to TGF-beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "John Mascarenhas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2011-02",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-12-08",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01291784"
    },
    {
      "nct_id": "NCT01611298",
      "title": "Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndrome",
        "Hodgkin Lymphoma",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tetanus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Robert Krance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "3 Years to 70 Years"
      },
      "enrollment_count": 7,
      "start_date": "2008-03",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01611298"
    },
    {
      "nct_id": "NCT00594555",
      "title": "A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia, Blast Crisis",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "CLAG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-11",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2008-10-31",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00594555"
    },
    {
      "nct_id": "NCT00002504",
      "title": "Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Precancerous/Nonmalignant Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hoag Memorial Hospital Presbyterian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1992-08",
      "completion_date": "1999-02",
      "has_results": false,
      "last_update_posted_date": "2011-05-12",
      "last_synced_at": "2026-07-24T06:22:24.870Z",
      "location_count": 5,
      "location_summary": "Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002504"
    }
  ]
}